Elan to Pay Shareholders Tysabri Dividends in Challenge to Bid

Elan Corp. said it will pay shareholders dividends from its royalties from multiple-sclerosis drug Tysabri in a challenge to a $6.5 billion bid from RP Management LLC for the Dublin-based drugmaker.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.